L06: Mavrilimumab in #GCA ⭐️Efficacy and safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV Sustained remission➡️ 33% ⬆️ in MAV No diff in new or relapsing/ref pts, No diff in AE #ACR20 #ACRambassador